Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma

McKelvey, Eugene M.; Gottlieb, Jeffrey A.; Wilson, Henry E.; Haut, Arthur; Talley, Robert W.; Stephens, Ronald L.; Lane, M. Daniel; Gamble, Jess F.; Jones, Stephen E.; Grozea, P; Gutterman, J. U.; Coltman, Charles A.; Moon, Thomas E.

doi:10.1002/1097-0142(197610)38:4<1484::aid-cncr2820380407>3.0.co;2-i

Cited by 759 publications

(185 citation statements)

References 15 publications

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…However, responses to initial chemotherapy and radiation therapy are effective in only a minority of patients (1). Anthracycline-containing regimens, specifically the classic CHOP, have been used as the main therapy for intermediate-and high-grade NHL since 1970 (2,3). Approximately 70 to 80% of the patients with aggressive NHL respond to CHOP, but many of them will relapse and only 40% can be cured.…”

Section: Introductionmentioning

confidence: 82%

“…According to intention to treat , 24 (72.7%) achieved complete remission. Six patients did not achieve complete remission after completion of the procedure, one patient is alive on therapy and five patients died because of progression of disease in a median time of 6 months (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14). One patient relapsed after complete remission for 12 months and is alive on therapy.…”

Section: Response and Survivalmentioning

confidence: 99%

See 1 more Smart Citation

High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma

Baldissera

Aranha

Oliveira

et al. 2002

Braz J Med Biol Res

View full text Add to dashboard Cite

Trials have demonstrated that high-dose escalation followed by autologous transplantation can promote better long-term survival as salvage treatment in malignant lymphomas. The aim of the present nonrandomized clinical trial was to demonstrate the role of high-dose cyclophosphamide (HDCY) in reducing tumor burden and also to determine the effectiveness of HDCY followed by etoposide (VP-16) and methotrexate (MTX) in Hodgkin s disease plus high-dose therapy with peripheral blood progenitor cell (PBPC) transplantation as salvage treatment. From 1998 to 2000, 33 patients with a median age of 33 years (13-65) affected by aggressive non-Hodgkin s lymphoma (NHL) (60.6%) or persistent or relapsed Hodgkin s disease (39.4%) were enrolled and treated using high dose escalation (HDCY + HDVP-16 plus HDMTX in Hodgkin s disease) followed by autologous PBPC transplantation. On an intention to treat basis, 33 patients with malignant lymphomas were evaluated. The overall median follow-up was 400 days (40-1233). Thirty-one patients underwent autografting and received a median of 6.19 x 10 6 /kg (1.07-29.3) CD34 + cells. Patients who were chemosensitive to HDCY (N = 22) and patients who were chemoresistant (N = 11) presented an overall survival of 96 and 15%, respectively (P<0.0001). Overall survival was 92% for chemosensitive patients and 0% for patients who were still chemoresistant before transplantation (P<0.0001). Toxicity-related mortality was 12% (four patients), related to HDCY in two cases and to transplant in the other two. HDCY + HDVP-16 plus HDMTX in only Hodgkin s disease followed by autologous PBPC proved to be effective and safe as salvage treatment for chemosensitive patients affected by aggressive NHL and Hodgkin s disease, with acceptable mortality rates related to sequential treatment.

show abstract

Section: Introductionmentioning

confidence: 82%

Section: Response and Survivalmentioning

confidence: 99%

High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma

Baldissera

Aranha

Oliveira

et al. 2002

Braz J Med Biol Res

View full text Add to dashboard Cite

show abstract

“…23,24 Patients with stage I lymphoma were treated with either radiotherapy only or with a combination of radiation and chemotherapy.…”

Section: Patientsmentioning

confidence: 99%

True

1999

Leukemia

View full text Add to dashboard Cite

Diffuse large B cell lymphoma (DLBL) constitutes the greatest percentage of adult non-Hodgkin's lymphomas and represents a diverse spectrum of lymphoid neoplasms. Clinicopathologic, phenotypic and genotypic findings were correlated and compared for 63 DLBL cases to investigate whether they represent clinically relevant subtypes. They were all cyclin D1 negative and were phenotypically divided into three groups, ie group I (CD5 + type, n = 11), group II (CD5 − CD10 + type, n = 19), and group III (CD5 − CD10 − type, n = 33). Data were correlated by observing the respective gene rearrangement and expression of BCL2 and BCL6. In clinical aspects, the group I cases demonstrated a significantly inferior survival than those of the other two groups (log-rank test, P = 0.016). Although rearrangement of BCL2 and BCL6 did not show any inclination to a specific subgroup, the immunohistochemical detection of BCL2 was less frequent, at a statistically significant level (P = 0.011), in group II (50%) than in group I (82%) and III (82%) cases. This appears to confirm the unique aspect of the CD5 − CD10 + type DLBL, indicating a certain relationship with the normal germinal center cells which usually lack BCL2 expression. The BCL6 protein expression was detected in most of the present DLBL cases (92%) irrespective of this grouping. These data suggest that the phenotypic delineation by the detection of CD5 and CD10 will improve our understanding of DLBL and be helpful in a future subgrouping of DLBL.

show abstract

“…One course of combination chemotherapy was continued for 7 days, and 4 or 5 courses were usually performed with 3 to 4-week off-drug periods until complete remission was obtained. Four children with Lymphoma were treated with cyclophosphamide, adriamycin, vincristine and prednisolone (McKelvey et al 1976). One of these children received L-asparaginase in addition to the above therapy.…”

Section: Patients and Therapymentioning

confidence: 99%